Show simple item record

dc.contributor.authorYing, Melissa A.
dc.contributor.authorMaruschak, Nadia
dc.contributor.authorMansur, Rodrigo Barbachan [UNIFESP]
dc.contributor.authorCarvalho, Andre F.
dc.contributor.authorCha, Danielle S.
dc.contributor.authorMcIntyre, Roger S.
dc.identifier.citationCns & Neurological Disorders-drug Targets. Sharjah: Bentham Science Publ Ltd, v. 13, n. 10, p. 1836-1845, 2014.
dc.description.abstractBackground: Cognitive deficits differentially affect individuals with type 2 diabetes mellitus (T2DM) and mood disorders. Accumulating evidence implicates disturbances in metabolism as salient to cognitive function. Thus, the mitigation of metabolic disturbances may preserve or ameliorate cognitive function. This review aims to evaluate available evidence investigating the effects of metformin on cognitive function as well as summarize putative mechanistic properties related to these clinical effects.Methods: A PubMed search was conducted using the search words including, but not limited to: metformin, Major Depressive Disorder, type 2 diabetes mellitus, and cognitive dysfunction. All English language articles published from 1990 to July 2014 were reviewed.Results: Extant preclinical and clinical data have been mixed, wherein both cognitive disruption and pro-cognitive effects have been reported with the administration of metformin. Sound mechanistic evidence supports metformin as a treatment; however, the heterogeneity of study designs has contributed to an inability to arrive at an unequivocal conclusion regarding metformin effects upon cognition.Conclusion: Available evidence does not provide a robust signal for improvement in cognition in either mood disorder or T2DM samples. Notwithstanding, it is premature to label metformin as a no-go agent for further testing and development for cognitive dysfunction. A well designed, proof-of-concept trial of metformin investigating its possible cognitive effects in mood disorders is therefore warranted.en
dc.publisherBentham Science Publ Ltd
dc.relation.ispartofCns & Neurological Disorders-drug Targets
dc.rightsAcesso restrito
dc.subjectCognitive deficitsen
dc.titleMetformin: Repurposing Opportunities for Cognitive and Mood Dysfunctionen
dc.contributor.institutionUniv Western Ontario
dc.contributor.institutionUniv Hlth Network
dc.contributor.institutionUniv Toronto
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionUniv Fed Ceara
dc.description.affiliationUniv Western Ontario, London, ON, Canada
dc.description.affiliationUniv Hlth Network, Mood Disorders Psychopharmacol Unit, Toronto, ON, Canada
dc.description.affiliationUniv Toronto, Toronto, ON, Canada
dc.description.affiliationFed Univ Sao Paulo UNIFESP, Dept Psychiat, LINC, Sao Paulo, Brazil
dc.description.affiliationUniv Fed Ceara, Fac Med, Translat Psychiat Res Grp, Fortaleza, Ceara, Brazil
dc.description.affiliationUniv Fed Ceara, Fac Med, Dept Clin Med, Fortaleza, Ceara, Brazil
dc.description.affiliationUniv Toronto, Inst Med Sci, Toronto, ON, Canada
dc.description.affiliationUniv Toronto, Dept Psychiat, Toronto, ON, Canada
dc.description.affiliationUniv Toronto, Dept Pharmacol, Toronto, ON, Canada
dc.description.affiliationUnifespFed Univ Sao Paulo UNIFESP, Dept Psychiat, LINC, Sao Paulo, Brazil
dc.description.sourceWeb of Science

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record